NumerixS Investment Technologies Inc grew its position in Acorda Therapeutics Inc (NASDAQ:ACOR) by 123.3% during the 1st quarter, HoldingsChannel reports. The firm owned 11,518 shares of the biopharmaceutical company’s stock after purchasing an additional 6,359 shares during the quarter. NumerixS Investment Technologies Inc’s holdings in Acorda Therapeutics were worth $152,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Ontario Teachers Pension Plan Board bought a new stake in Acorda Therapeutics during the 4th quarter worth about $1,210,000. Dupont Capital Management Corp bought a new stake in Acorda Therapeutics during the 1st quarter worth about $280,000. Convergence Investment Partners LLC bought a new stake in Acorda Therapeutics during the 4th quarter worth about $274,000. Two Sigma Investments LP bought a new stake in Acorda Therapeutics during the 4th quarter worth about $2,509,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Acorda Therapeutics during the 4th quarter worth about $44,000.
Shares of ACOR stock opened at $7.60 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.30 and a quick ratio of 3.97. The stock has a market capitalization of $342.20 million, a PE ratio of 4.18 and a beta of 1.37. Acorda Therapeutics Inc has a one year low of $6.96 and a one year high of $31.95.
A number of brokerages have recently commented on ACOR. BidaskClub cut Acorda Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 29th. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, May 7th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, March 19th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $19.30.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2019/06/14/acorda-therapeutics-inc-nasdaqacor-stake-raised-by-numerixs-investment-technologies-inc.html.
Acorda Therapeutics Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
Featured Article: What does a market perform rating mean?
Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics Inc (NASDAQ:ACOR).
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.